Erythrocyte Membrane and Plasma Fatty Acids Composition in Patients with Coronary Heart Disease Requiring Percutaneous Angioplasty

Main Article Content

Takeshi Arita
Taku Yokoyama
Mitsuhiro Fukata
Toru Maruyama
Seira Hazeyama
Shiro Mawatari
Takehiko Fujino
Koichi Akashi

Abstract

Aims: Atherosclerosis is associated with oxidative stress and fatty acid composition plays a critical role in vascular endothelial dysfunction and injury leading to the coronary atherosclerotic progression. However, the correlation between the fatty acid profile and coronary atherosclerosis is debatable. The goal of this study is to assess the erythrocyte membrane and plasma fatty acid composition in patients with coronary heart disease.

Methods: The erythrocyte membrane and plasma distributions of fatty acids were quantified in patients with coronary heart disease (n = 30, group A) which needs both intensive medication and elective percutaneous coronary intervention and age-matched controls (n = 38, group B) using high-performance liquid chromatography combined with evaporative light scattering detection method. Baseline data were extracted from medical records.

Results: Logistic regression analysis demonstrated that hypoalbuminemia (p = 0.010) and HbA1c (p = 0.005) are associated with required percutaneous coronary intervention. Although appropriate logistic regression model for percutaneous coronary intervention could not be obtained by incorporating fatty acid components, percutaneous coronary intervention was correlated mostly to the increased oleic acid and decreased stearic acid in both erythrocyte membrane and plasma in receiver-operating characteristic analysis.

Conclusion: This single-center, cross-sectional study indicated that erythrocyte membrane and plasma fatty acids have a potential impact on the coronary atherosclerotic progression which requires coronary intervention. Longitudinal studies are necessary to clarify the clinical role of fatty acids distribution as a novel atherogenic marker.

Keywords:
Coronary heart disease, percutaneous angioplasty, erythrocyte membrane, fatty acids.

Article Details

How to Cite
Arita, T., Yokoyama, T., Fukata, M., Maruyama, T., Hazeyama, S., Mawatari, S., Fujino, T., & Akashi, K. (2020). Erythrocyte Membrane and Plasma Fatty Acids Composition in Patients with Coronary Heart Disease Requiring Percutaneous Angioplasty. Cardiology and Angiology: An International Journal, 9(2), 21-30. https://doi.org/10.9734/ca/2020/v9i230132
Section
Original Research Article

References

Siti HN, Kamisah Y, Kamsiah J. The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review). Vascul Pharmacol. 2015;71:40-56.

Förstermann U, Xia N, Li H. Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circ Res. 2017;120(4):713-735.

Mawatari S, Murakami K. Analysis of membrane phospholipid peroxidation by isocratic high-performance liquid chromatography with ultraviolet detection. Anal Biochem. 1998;264(1):118-123.

Okamoto K, Maruyama T, Kaji Y, Harada M, Mawatari S, Fujino T, Uyesaka N. Verapamil prevents impairment in filterability of human erythrocytes exposed to oxidative stress. Jpn J Physiol. 2004; 54(1):39-46.

Lang F, Abed M, Lang E, Föller M. Oxidative stress and suicidal erythrocyte death. Antioxid Redox Signal. 2014;21(1): 138-153.

Siener R, Alteheld B, Terjung B, Junghans B, Bitterlich N, Stehle P, Metzner C. Change in the fatty acid pattern of erythrocyte membrane phospholipids after oral supplementation of specific fatty acids in patients with gastrointestinal diseases. Eur J Clin Nutr. 2010;64(4):410-418.

Arita T, Yokoyama T, Moriyama S, Irie K, Fukata M, Odashiro K, Maruyama T, Hazeyama S, Mawatari S, Fujino T, Akashi K. Plasma and erythrocyte membrane plasmalogens in patients with coronary heart diseases undergoing percutaneous intervention. Cardiol Angiol Int J. 2018; 7(4):1-11.

Braverman NE, Moser AB. Functions of plasmalogen lipids in health and disease. Biochim Biophys Acta. 2012;1822(9): 1442-1452.

Lessig J, Fuchs B. Plasmalogens in biological systems: Their role in oxidative processes in biological membranes, their contribution to pathological processes and aging and plasmalogen analysis. Curr Med Chem. 2009;16(16):2021-2041.

Ohta Y, Tsuchihashi T, Onaka U, Hasegawa E. Clustering of cardiovascular risk factors and blood pressure control status in hypertensive patients. Intern Med. 2010;49(15):1483-1487.

Matsuzawa Y. Metabolic syndrome: Definition and diagnostic criteria in Japan. J Atheroscler Thromb. 2005;12(6):301.

Mawatari S, Hazeyama S, Fujino T. Measurement of ether phospholipids in human plasma with HPLC-ELSD and LC/ESI-MS after hydrolysis of plasma with phospholipase A1. Lipids. 2016;51(8):997-1006.

Mawatari S, Okuma Y, Fujino T. Separation of intact plasmalogens and all other phospholipids by a single run of high-performance liquid chromatography. Anal Biochem. 2007;370(1):54-59.

Noda H, Moriyama S, Irie K, Fujita K, Yokoyama T, Fukata M, Arita T, Odashiro K, Maruyama T, Mawatari S, Fujino T, Akashi K. Erythrocyte membrane plasmalogen contents diminished in severe atherosclerotic patients undergoing invasive endovascular therapy. Membrane. 2017;42(6):242-249.

Fujihara M, Fukata M, Odashiro K, Maruyama T, Akashi K, Yokoi Y. Reduced plasma eicosapentaenoic acid-arachidonic acid ratio in peripheral artery disease. Angiology. 2013;64(2):112-118.

Steffen BT, Duprez D, Szklo M, Guan W, Tsai MY. Circulating oleic acid levels are related to greater risks of cardiovascular events and all-cause mortality: The multi-ethnic study of atherosclerosis. J Clin Lipidol. 2018;12(6):1404-1412.

Perdomo L, Beneit N, Otero YF, Escribano Ó, Díaz-Castroverde S, Gómez-Hernández A, Benito M. Protective role of oleic acid against cardiovascular insulin resistance and in the early and late cellular atherosclerotic process. Cardiovasc Diabetol. 2015;14:75.
DOI: 10.1186/s12933-015-0237-9

Nishimukai M, Maeba R, Yamazaki Y, Nezu T, Sakurai T, Takahashi Y, Hui SP, Chiba H, Okazaki T, Hara H. Serum choline plasmalogens-those with oleic acid in sn-2- are biomarkers for coronary artery disease. Clin Chim Acta. 2014;437:147-154.

Santaren ID, Watkins SM, Liese AD, Wagenknecht LE, Rewers MJ, Haffner SM, Lorenzo C, Festa A, Bazinet RP, Hanley AJ. Individual serum saturated fatty acids and markers of chronic subclinical inflammation: The Insulin Resistance Atherosclerosis Study. J Lipid Res. 2017; 58(11):2171-2179.

Zeng J, Zhang Y, Hao J, Sun Y, Liu S, Bernlohr DA, Sauter ER, Cleary MP, Suttles J, Li B. Stearic acid induces CD11c expression in proinflammatory macrophages via epidermal fatty acid binding protein. J Immunol. 2018;200(10): 3407-3419.

Harvey KA, Walker CL, Xu Z, Whitley P, Pavlina TM, Hise M, Zaloga GP, Siddiqui RA. Oleic acid inhibits stearic acid-induced inhibition of cell growth and pro-inflammatory responses in human aortic endothelial cells. J Lipid Res. 2010; 51(12):3470-80.

Mawatari S, Katafuchi T, Miake K, Fujino T. Dietary plasmalogen increases erythrocyte membrane plasmalogen in rats. Lipids Health Dis. 2012;11:161.
DOI: 10.1186/1476-511X-11-161

Katafuchi T, Ifuku M, Mawatari S, Noda M, Miake K, Sugiyama M, Fujino T. Effects of plasmalogens on systemic lipopolysaccharide-induced glial activation and β-amyloid accumulation in adult mice. Ann NY Acad Sci. 2012;1262: 85-92.

Oma S, Mawatari S, Saito K, Wakana C, Tsuboi Y, Yamada T, Fujino T. Changes in phospholipid composition of erythrocyte membrane in Alzheimer’s disease. Dement Geriatr Cogn Dis Extra. 2012;2(1):298-303.

Fujino T, Yamada T, Asada T, Tsuboi Y, Wakana C, Mawatari S, Kono S. Efficacy and blood plasmalogen changes by oral administration of plasmalogen in patients with mild Alzheimer’s disease and mild cognitive impairment: A multicenter, randomized, double-blind, placebo-controlled trial. EBioMedicine. 2017;17: 199-205.

Ebisawa S, Kashima Y, Miyashita Y, Yamazaki S, Abe N, Saigusa T, Miura T, Motoki H, Izawa A, Ikeda U. Impact of endovascular therapy on oxidative stress in patients with peripheral artery disease. Circ J. 2014;78(6):1445- 1450.